Jathin Bandari - Jan 19, 2024 Form 4 Insider Report for Protara Therapeutics, Inc. (TARA)

Role: Chief Medical Officer
Signature: /s/ Mary Grendell, Attorney-in-Fact
Stock symbol: TARA
Transactions as of: Jan 19, 2024
Transactions value $: -$5,499
Form type: 4
Date filed: 1/23/2024, 04:05 PM
Previous filing: Jan 12, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TARA	Common Stock	Award	$0	+23K	+62.87%	$0.00	59.6K	Jan 19, 2024	Direct	F1
transaction	TARA	Common Stock	Tax liability	-$5.5K	-2.88K	-4.83%	$1.91	56.7K	Jan 19, 2024	Direct	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TARA	Stock Option (Right to Buy)	Award	$0	+137K		$0.00	137K	Jan 19, 2024	Common Stock	137K	$1.91	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares being reported are being issued pursuant to restricted stock unit awards (RSUs), each of which represents a contingent right to receive one share of Issuer's common stock. The RSUs vest in equal one-third installments on the first, second and third anniversaries of January 19, 2024.
F2	25% of the shares vest on the one year anniversary of January 19, 2024 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.
F3	Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on January 19, 2023.